Liao let go of the Chinese medicine formula particles in the national blank area is not much left

On June 19th, Liaoning Provincial Health and Planning Commission, Industry and Information Technology Commission and Food and Drug Administration jointly issued the Notice on the Declaration of Special Projects for Research on Chinese Medicine Formula Particles in Liaoning Province (hereinafter referred to as Notification).Liaoning formula particles, the declaration threshold is not high
Liaoning Chinese medicine formula particles project procedures are as follows: the Industry and Information Technology Commission organized the declaration of pharmaceutical enterprises, the three departments jointly selected pharmaceutical enterprises, by the provincial food and drug regulatory bureau on-site inspection, in line with the requirements of the grant of the record. After filing, pharmaceutical companies can carry out research work on the safety and effectiveness of Chinese medicine formula particles.the declaration conditions are four:
Liaoning Province obtained the "Drug Production Enterprise License" (within the validity period) and has the scope of production of particulate agents pharmaceutical production enterprises.
has a complete production capacity of Chinese medicine tablets, extraction, concentration, drying, granulation, etc., in line with the "Drug Production Quality Management Code" (GMP) requirements.
enterprises have completed more than 200 kinds of Chinese medicine formula particle quality standards and other research work.
enterprises should have the corresponding research and development conditions and funding capacity, which can provide guarantee for project research.formulation particles provinces have been liberalized, the market pattern has been set
Liaoning "notice" shows that qualified pharmaceutical companies to obtain the record qualification, can provide the target hospital with Chinese medicine formula particles. Medical associations within the size of medical institutions can be used, separate hospitals are limited to more than two. The deadline for processing this document is June 29, 2018.
Liaoning's liberalization is also homeopathy.
At present, there are national pilot and provincial scientific research projects in the provinces have reached 55%, accounting for 60% of the end-sales of Chinese herbal medicine and Chinese medicine, if you count the national pilot enterprises KangRenTang base in Tianjin Wuqing, Guangdong side base in Shandong, then the country's blank areas are not much left.a fait tit-for-like fact, don't wait for the national document
From the above data, although there are still 30% of the provinces, the Chinese medicine formula particles have not been liberalized, but its sales accounted for less than 20%, can not affect the overall pattern.
addition, At present, Chinese traditional medicine is planning to set up production bases in many places to deal with local protection even in provinces that have not been liberalized, the enterprise into the establishment of points, can still cause the fact that the formula particles open.
based on this, although on March 1, 2016, the former State Administration of Food and Drug Administration issued the "Chinese medicine formula particle management measures (draft for comments)", the official national version of the document has not yet been issued. But don't wait, the formula particles quietly, has taken root, a fait tit-for-t know.
health insurance can directly affect the fate, as well as local protection
enjoy can be increased, do not account for the proportion of drugs and other policy advantages, whether hospitals or enterprises, have a relatively large expectation of it. The so-called visible policy dividend.
But for the industry, it is important to be reminded that health-care uncertainties can also have a direct impact on the industry's fortunes;
, the replacement ratio of drinking tablets, whether the sales potential can be estimated to the expectations of enterprises, etc., are the core points to pay attention to. (Seber Blue)